U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07333183) titled 'A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD' on Jan. 08.
Brief Summary: This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
Study Start Date: Dec. 23, 2025
Study Type: INTERVENTIONAL
Condition:
Pulmonary Hypertension
Interstitial Lung Disease (ILD)
Lung Diseases
Vascular Diseases
Cardiovascular Diseases
Fibrosis
Intervention:
DRUG: inhaled mosliciguat
Dose level 1, 2, or 3 for inhalation
DEVICE: Dry ...